[en] Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment. A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab. We show that vascular morphology was normalised over the time period investigated, but vascular function was not improved, resulting in poor tumoural blood flow and increased hypoxia.
Disciplines :
Oncologie
Auteur, co-auteur :
Obad, Nina; 1 Department of Biomedecine, University of Bergen, Bergen, Norway. ; 2 Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway. ; 3 KG Jebsen Brain Tumor research Center, University of Bergen, Bergen, Norway.
Espedal, Heidi; 1 Department of Biomedecine, University of Bergen, Bergen, Norway. ; 3 KG Jebsen Brain Tumor research Center, University of Bergen, Bergen, Norway.
Jirik, Radovan; 4 Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
Sakariassen, Per Oystein; 1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Brekke Rygh, Cecilie; 1 Department of Biomedecine, University of Bergen, Bergen, Norway. ; 5 Bergen University College, Bergen, Norway.
Lund-Johansen, Morten; 2 Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway. ; 6 Department of Clinical Science, University of Bergen, Bergen, Norway.
Taxt, Torfinn; 1 Department of Biomedecine, University of Bergen, Bergen, Norway.
NICLOU, Simone P. ; 3 KG Jebsen Brain Tumor research Center, University of Bergen, Bergen, Norway. ; 7 Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Bjerkvig, Rolf; 1 Department of Biomedecine, University of Bergen, Bergen, Norway. ; 3 KG Jebsen Brain Tumor research Center, University of Bergen, Bergen, Norway. ; 7 Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Keunen, Olivier; 7 Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Co-auteurs externes :
yes
Langue du document :
Anglais
Titre :
Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.
Louis DN, Ohgaki H, Wiestler OD, The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109
Vredenburgh JJ, Desjardins A, Herndon JE, 2nd Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253–1259
Kreisl TN, Kim L, Moore K, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740–745
Macdonald DR, Cascino TL, Schold SC, Jr Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–1280
Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–4740
Chinot OL, Wick W, Mason W, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709–722
Gilbert MR, Dignam JJ, Armstrong TS, A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699–708
van den Bent MJ, Vogelbaum MA, Wen PY, End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s criteria. J Clin Oncol 2009; 27: 2905–2908
Reardon DA, Desjardins A, Peters KB, Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011; 117: 5351–5358
Taal W, Oosterkamp HM, Walenkamp AM, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014; 15: 943–953
Wick W. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol 2015; 17(suppl-5): v1
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987–989
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417–427
Winkler F, Kozin SV, Tong RT, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553–563
Tong RT, Boucher Y, Kozin SV, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731–3736
McGee MC, Hamner JB, Williams RF, Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 76: 1537–1545
Claes A, Wesseling P, Jeuken J, Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7: 71–78
Arjaans M, Oude Munnink TH, Oosting SF, Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013; 73: 3347–3355
Sorensen AG, Emblem KE, Polaskova P, Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012; 72: 402–407
Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83–95
Batchelor TT, Gerstner ER, Emblem KE, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013; 110: 19059–19064
Keunen O, Johansson M, Oudin A, Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011; 108: 3749–3754
Bjerkvig R, Tonnesen A, Laerum OD, Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 1990; 72: 463–475
Wang J, Miletic H, Sakariassen PO, A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 2009; 9: 465
Stieber D, Golebiewska A, Evers L, Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 2014; 127: 203–219
Sakariassen PO, Prestegarden L, Wang J, Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 2006; 103: 16466–16471
Taxt T, Jirik R, Rygh CB, Single-channel blind estimation of arterial input function and tissue impulse response in DCE-MRI. IEEE Trans Biomed Eng 2012; 59: 1012–1021
Kickingereder P, Wiestler B, Graf M, Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2015; 121: 373–380
Bougnaud S, Golebiewska A, Oudin A, Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget 2016; 7: 31955–31971
O'Connor JP, Rose CJ, Waterton JC, Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 2015; 21: 249–257
Bonekamp D, Mouridsen K, Radbruch A, Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma. J Cereb Blood Flow Metab 2016; 37(2): 485–494
Wen PY, Macdonald DR, Reardon DA, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963–1972
Schmainda KM, Zhang Z, Prah M, Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015; 17: 1148–1156
Pope WB, Kim HJ, Huo J, Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252: 182–189
Ellingson BM, Cloughesy TF, Lai A, Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011; 13: 1151–1161
Chen L, Liu M, Bao J, The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One 2013; 8: e79008
Wong ET, Gautam S, Malchow C, Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011; 9: 403–407
